title: Recent Advances in the Treatment of Immune-Mediated Inflammatory Diseases.
abstract: The treatment of immune-mediated inflammatory diseases (IMIDs) has dramatically improved over the last two decades by the development of a series of targeted biological therapies. This paper focuses on new developments in the treatment of IMIDs. In particular, we discuss how different ways of targeting the same mediators can lead to different efficacy and safety profiles, using B cell targeting as example. In addition, we discuss the emerging field of 'small molecules' that target specifically intracellular processes related to cytokine signaling, cell activation, cell migration, and other processes relevant to tissue inflammation.
authors.affiliation: Department of Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 22600, 1105, Amsterdam, The Netherlands.|Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors.forename: Sander W
authors.initials: SW
authors.lastname: Tas
authors.affiliation: Department of Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 22600, 1105, Amsterdam, The Netherlands. d.l.baeten@amc.uva.nl.|Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. d.l.baeten@amc.uva.nl.
authors.forename: Dominique L P
authors.initials: DL
authors.lastname: Baeten
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D018951:Antigens, CD20 / Q000378:metabolism; D000954:Antigens, Surface / Q000378:metabolism; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D053612:Janus Kinases / Q000037:antagonists & inhibitors; D020935:MAP Kinase Signaling System / Q000187:drug effects; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D000954:Antigens, Surface; D016328:NF-kappa B; D047428:Protein Kinase Inhibitors; D053612:Janus Kinases
keywords: B cells; Immune-mediated inflammatory diseases; Signal transduction; Treatment